for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agilent Technologies Inc

A.N

Latest Trade

82.21USD

Change

0.68(+0.83%)

Volume

685,367

Today's Range

81.84

 - 

82.41

52 Week Range

62.00

 - 

82.41

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Agilent Technologies Increases Cash Dividend To 18 Cents Per Share

Nov 20 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT TECHNOLOGIES INCREASES CASH DIVIDEND TO 18 CENTS PER SHARE.AGILENT TECHNOLOGIES INC - QUARTERLY DIVIDEND OF 18 CENTS PER SHARE REFLECTS A 10% INCREASE OVER PREVIOUS QUARTER'S DIVIDEND.

Agilent Technologies Announces Pricing Of $500 Million Of Senior Notes

Agilent Technologies Inc <A.N>::AGILENT TECHNOLOGIES ANNOUNCES PRICING OF $500 MILLION OF SENIOR NOTES.AGILENT TECHNOLOGIES INC - NOTES WILL MATURE IN SEPTEMBER 2029 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 2.750 PERCENT.

Agilent Technologies Announces Proposed Offering Of Senior Notes

Sept 5 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT TECHNOLOGIES ANNOUNCES PROPOSED OFFERING OF SENIOR NOTES.AGILENT - INTENDS TO USE NET PROCEEDS FROM OFFERING &, TO EXTENT NECESSARY, CASH ON HAND, TO FUND REDEMPTION OF ITS 5.00% SENIOR NOTES DUE 2020.

Agilent Technologies Says Q3 GAAP Earnings Per Share $0.60

Aug 14 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT TECHNOLOGIES REPORTS THIRD QUARTER FISCAL YEAR 2019 FINANCIAL RESULTS.SEES Q4 2019 NON-GAAP EARNINGS PER SHARE $0.84 TO $0.86.Q3 NON-GAAP EARNINGS PER SHARE $0.76.Q3 GAAP EARNINGS PER SHARE $0.60.SEES Q4 2019 REVENUE $1.31 BILLION TO $1.33 BILLION.Q3 REVENUE $1.27 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.24 BILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $3.07 TO $3.09.SEES FY 2019 REVENUE $5.105 BILLION TO $5.125 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.72 -- REFINITIV IBES DATA.RAISES FULL-YEAR REVENUE AND NON-GAAP EPS GUIDANCE.Q4 EARNINGS PER SHARE VIEW $0.87, REVENUE VIEW $1.34 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $3.05, REVENUE VIEW $5.11 BILLION -- REFINITIV IBES DATA.

Agilent Technologies Says Entered Amendment No.1 To Credit Agreement & Incremental Assumption Agreement Amending March 13 Dated Credit Agreement

Aug 8 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT TECHNOLOGIES - ON AUG. 7, ENTERED AMENDMENT NO. 1 TO CREDIT AGREEMENT & INCREMENTAL ASSUMPTION AGREEMENT AMENDING MARCH 13 DATED CREDIT AGREEMENT.AGILENT SAYS INCREMENTAL AMENDMENT PROVIDES FOR A $500 MILLION 364-DAY, NON-AMORTIZING INCREMENTAL TERM FACILITY MATURING ON AUG. 5, 2020 - SEC FILING.

Agilent Settles Key Intellectual Property Case In China

July 31 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT SETTLES KEY INTELLECTUAL PROPERTY CASE IN CHINA.AGILENT TECHNOLOGIES- CO REACHED AGREEMENT WITH ECHROM AND PANNATEK, AS WELL AS CERTAIN FORMER AGILENT EMPLOYEES, REGARDING AN INTELLECTUAL PROPERTY DISPUTE.

Agilent Companion Diagnostic Gains Expanded FDA Approval

July 31 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT COMPANION DIAGNOSTIC GAINS EXPANDED FDA APPROVAL IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC).U.S. FOOD AND DRUG ADMINISTRATION HAS APPROVED COMPANY'S PD-L1 IHC 22C3 PHARMDX ASSAY FOR EXPANDED USE.

Agilent Technologies To Acquire Biotek Instruments For $1.165 Billion

July 11 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT TO ACQUIRE BIOTEK, STRENGTHENING LEADERSHIP POSITION IN GROWING CELL ANALYSIS SEGMENT.AGILENT TECHNOLOGIES - WITH ANTICIPATED TAX BENEFITS FOR CO, NET PURCHASE PRICE EXPECTED TO BE ABOUT $1.05 BILLION .AGILENT TECHNOLOGIES INC - SIGNED A DEFINITIVE AGREEMENT TO ACQUIRE PRIVATELY-OWNED BIOTEK INSTRUMENTS FOR $1.165 BILLION.AGILENT TECHNOLOGIES INC - AGILENT EXPECTS ACQUISITION WILL BE ACCRETIVE TO NON-GAAP EARNINGS PER SHARE, CONTRIBUTING $0.02-$0.04 FOR FISCAL YEAR 2020.

Agilent Companion Diagnostic Gains Expanded FDA Approval In Head And Neck Squamous Cell Carcinoma

June 11 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT COMPANION DIAGNOSTIC GAINS EXPANDED FDA APPROVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC).AGILENT TECHNOLOGIES INC - AGILENT COMPANION DIAGNOSTIC GAINS EXPANDED FDA APPROVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC).AGILENT TECHNOLOGIES INC - PD-L1 IHC 22C3 PHARMDX CAN NOW BE USED AS AN AID TO IDENTIFY HNSCC PATIENTS FOR TREATMENT WITH KEYTRUDA(PEMBROLIZUMAB).AGILENT TECHNOLOGIES INC - PD-L1 IHC 22C3 PHARMDX CAN NOW BE USED AS AN AID TO IDENTIFY HNSCC PATIENTS FOR TREATMENT WITH KEYTRUDA.

Agilent Technologies Reports Q2 Earnings Per Share $0.57

May 14 (Reuters) - Agilent Technologies Inc <A.N>::AGILENT TECHNOLOGIES REPORTS SECOND QUARTER FISCAL YEAR 2019 FINANCIAL RESULTS.SEES Q3 2019 NON-GAAP EARNINGS PER SHARE $0.71 TO $0.73.Q2 NON-GAAP EARNINGS PER SHARE $0.71.Q2 EARNINGS PER SHARE $0.57.SEES Q3 2019 REVENUE $1.225 BILLION TO $1.245 BILLION.Q2 REVENUE $1.24 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.27 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.72 -- REFINITIV IBES DATA.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $3.03 TO $3.07.SEES FY 2019 REVENUE $5.085 BILLION TO $5.125 BILLION.Q3 EARNINGS PER SHARE VIEW $0.73, REVENUE VIEW $1.27 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $3.07, REVENUE VIEW $5.19 BILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up